Logo

American Heart Association

  20
  0


Final ID: MP460

Temporal Trends in Major Adverse Cardiovascular Events Following Hospitalization for Myocardial Infarction Between 2008-2022: Insights from the Veterans Affairs Healthcare System

Abstract Body (Do not enter title and authors here): Background:
Over 800,000 individuals are hospitalized for a myocardial infarction (MI) annually in the United States. Temporal trends in post-discharge outcomes are uncertain.

Question:
Among Veterans who survive an MI hospitalization, how have post-discharge outcomes changed?

Methods:
Veterans who survived an MI hospitalization within or outside the VHA between 2008-2022 were identified based on a principal diagnosis of MI from an acute care hospitalization. We identified comorbidities, vital signs, and laboratory values pre-hospitalization.
The primary outcome was a 4-point composite MACE (death, MI, ischemic stroke, and heart failure (HF) hospitalization) over 1 year post-discharge. Temporal trends were analyzed by comparing outcomes across 3 time periods (2008-2012, 2013-2017, and 2018-2022) with the Cuzick rank test. We also evaluated 1-year death alone and performed a landmark analysis evaluating 1-year death following HF hospitalization within the first 12 months post-MI. The annual change in outcomes was examined while adjusting for demographics, comorbidities, pre-admission vital signs and laboratory values, and STEMI vs. NSTEMI classification.


Results:
There were 444,659 Veterans with a non-fatal MI hospitalization between 2008 and 2022. The median age was 73 (interquartile range: 66-80) and 1.8% were women. Over time, the proportion with STEMI decreased (2008-2012: 26.1%, 2013-2017: 23.1%, and 2018-2022: 23.1%; p<0.01). The proportion with inpatient revascularization decreased from 49.6% to 48.1% to 36.9% (p<0.01).
The 1-year risk of the composite MACE outcome decreased from 26.1% to 23.2% to 22.2% (p<0.01) across time periods. After adjustment, there was a 3.9% annual relative decrease in the odds of 1-year MACE (OR: 0.965; 95% CI: 0.963-0.967). The risk of 1-year death post-MI hospitalization decreased from 20.7% to 18.1% to 16.3% (p<0.01) (Figure). After adjustment, there was a 4.2% annual relative decrease in the odds of 1-year mortality (OR 0.958 per year; 95% CI: 0.956-0.960).
There were 23,048 (5.2%) Veterans with HF hospitalization within 12 months of MI discharge. Among this cohort, 44.9% died within 1-year post-HF hospitalization.

Conclusion:
Among Veterans, the risk of death post-MI hospitalization has improved over time. However, over 1 in 5 Veterans post-MI continue to have major adverse cardiovascular outcomes within 1 year. Veterans with a HF hospitalization post-MI are at substantially elevated risk of death.
  • Sandhu, Alexander  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Skaar, Jeffrey  ( Novo Nordisk , Plainsboro , New Jersey , United States )
  • Tonnu-mihara, Ivy  ( Novo Nordisk Inc. , Huntington Beach , California , United States )
  • Furst, Adam  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Rodriguez, Fatima  ( STANFORD UNIVERSITY , Palo Alto , California , United States )
  • Kalwani, Neil  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Maron, David  ( Stanford University , Millbrae , California , United States )
  • Nallamshetty, Shriram  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Din, Natasha  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Fan, Michael  ( Novo Nordisk , Los Angeles , California , United States )
  • Khachatourian, Kat  ( Novo Nordisk , Plainsboro , New Jersey , United States )
  • Author Disclosures:
    Alexander Sandhu: DO have relevant financial relationships ; Consultant:Reprieve Cardiovascular:Active (exists now) ; Consultant:Clearly:Active (exists now) ; Research Funding (PI or named investigator):NOVO NORDISK:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):Astra Zeneca:Active (exists now) | Jeffrey Skaar: DO have relevant financial relationships ; Employee:Novo Nordisk:Active (exists now) ; Individual Stocks/Stock Options:Trinity Life Sciences:Active (exists now) ; Individual Stocks/Stock Options:Novo Nordisk:Active (exists now) | Ivy Tonnu-Mihara: DO have relevant financial relationships ; Employee:NNI:Active (exists now) | Adam Furst: DO NOT have relevant financial relationships | Fatima Rodriguez: DO have relevant financial relationships ; Consultant:HealthPals:Past (completed) ; Consultant:Cleerly Health:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:iRhythm:Active (exists now) ; Consultant:HeartFlow:Active (exists now) ; Consultant:Arrowhead Pharmaceuticals:Active (exists now) ; Consultant:Edwards:Active (exists now) ; Consultant:Inclusive Health:Active (exists now) ; Consultant:Esperion Therapeutics:Past (completed) ; Consultant:Kento Health:Active (exists now) ; Consultant:Movano Health:Active (exists now) ; Consultant:NovoNordisk:Past (completed) ; Consultant:Novartis:Active (exists now) | Neil Kalwani: DO NOT have relevant financial relationships Shriram Nallamshetty: No Answer | Natasha Din: DO NOT have relevant financial relationships | Michael Fan: DO have relevant financial relationships ; Employee:Novo Nordisk:Active (exists now) ; Individual Stocks/Stock Options:Novo Nordisk:Active (exists now) | Kat Khachatourian: DO have relevant financial relationships ; Employee:Novo Nordisk:Active (exists now) ; Individual Stocks/Stock Options:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Multiple Axes of Risk: Cardiometabolic Underpinnings of Myocardial, Atherosclerotic and Arrhythmic Disease

Saturday, 11/08/2025 , 03:15PM - 04:30PM

Moderated Digital Poster Session

More abstracts on this topic:
A Diagnosis Dilemma of Positional Hypoxia: Scoliosis-Mediated Platypnea-Orthodeoxia Syndrome

Ademuwagun Christianah, Arjoon Roy, Seth Paula, Chang Gene, Ibe Oby

Absence of standard modifiable risk factors (SMuRF-less) among 5002 Middle Eastern patients with atherosclerotic cardiovascular disease: (Interim analysis from the Jo-SMuRF Study)

Aldalal'ah Mo'men, Hammoudeh Ayman, Hamza Ibrahem, Alqudah Mohammad, Khasawneh Hasan, Alomari Sawsan, Alomari Ahmad, H. Assaf Sarah, Zaqqa Ayah, Khatatbeh Moawiah

More abstracts from these authors:
Patient-Reported Health Status Among Patients with Heart Failure with Improved Ejection Fraction

Vasti Elena, Zheng Jimmy, Kalwani Neil, Dejong Colette, Bhatt Ankeet, Ambrosy Andrew, Din Natasha, Heidenreich Paul, Sandhu Alexander


Clinical Outcomes Among Individuals with Persistent Systemic Inflammation Following Myocardial Infarction: Insights from the Veterans Affairs Healthcare System

Sandhu Alexander, Tonnu-mihara Ivy, Furst Adam, Rodriguez Fatima, Kalwani Neil, Nallamshetty Shriram, Din Natasha, Fan Michael, Khachatourian Kat, Skaar Jeffrey

You have to be authorized to contact abstract author. Please, Login
Not Available